BioTech/Drugs - N/A, N/A, US
Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.
Squarespace ECommerce
Gmail
NSOne
Typekit
Mobile Friendly